EE406 Economic Impact of Upadacitinib for the Treatment of Moderate-to-Severe Crohn’s Disease and Ulcerative Colitis: Induction and Maintenance Phase 3 Results on Work Productivity Loss
Jun 1, 2024, 00:00 AM
10.1016/j.jval.2024.03.702
https://www.valueinhealthjournal.com/article/S1098-3015(24)00817-9/fulltext
Section Title :
Section Order :
10174
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(24)00817-9&doi=10.1016/j.jval.2024.03.702